The Rise of Jasveen Sangha: How the Ketamine Queen Redefined Psychedelic Culture

Published 28 May 2026

The name Jasveen Sangha—often dubbed the ketamine queen by both admirers and critics—has become synonymous with the intersection of psychedelic medicine and countercultural rebellion. A figure who straddles the line between clinical legitimacy and underground mystique, Sangha’s influence extends from private ketamine clinics in California to viral TikTok tutorials on "dissociation as therapy." Her work has forced a reckoning: Can ketamine, a drug once confined to veterinary medicine and emergency rooms, be reclaimed as a tool for healing—or is it merely the latest frontier for those chasing the high?

What makes Sangha’s story compelling is not just her unapologetic embrace of ketamine’s psychedelic properties, but her ability to articulate its duality: a pharmaceutical with FDA approval for treatment-resistant depression, yet a substance that, in her hands, becomes a ritualistic experience. Critics dismiss her as a charlatan; others see her as a pioneer. The debate itself reveals deeper tensions in psychedelic culture, where science and spirituality collide. Her clinics, often shrouded in secrecy, have become pilgrimage sites for those seeking what she calls "controlled chaos"—a phrase that encapsulates her philosophy.

Sangha’s rise mirrors the broader resurgence of ketamine in mental health circles, a trend accelerated by Silicon Valley’s embrace of "biohacking" and the mainstream’s growing acceptance of psychedelics. Yet, unlike her peers in the psychedelic renaissance—such as the MDMA therapists or psilocybin advocates—she operates in a gray area, blending medical discourse with performance art. Her Instagram posts, which oscillate between clinical infographics and surreal selfies in ketamine-induced states, have cultivated a cult following. But her methods, which include intravenous administration in non-medical settings, have also drawn scrutiny from regulatory bodies.

The Complete Overview of Jasveen Sangha and the Ketamine Queen Phenomenon

The ketamine queen moniker wasn’t bestowed by accident. Jasveen Sangha, a former nurse turned psychedelic entrepreneur, has deliberately positioned herself as the public face of ketamine’s dissociative potential—a far cry from the anesthetic’s original medical use. Her clinics, such as Ketamine Wellness Centers in Los Angeles and San Francisco, offer "experiential therapy," where patients undergo IV ketamine sessions in environments designed to mimic the "ketamine room" aesthetic popularized by her social media presence. This approach diverges sharply from traditional ketamine-assisted psychotherapy, which emphasizes structured sessions with trained therapists.

Sangha’s model thrives on ambiguity. She markets ketamine as both a medical intervention and a lifestyle choice, a stance that has alienated some in the mental health community while attracting a clientele that includes tech executives, artists, and even celebrities seeking "cognitive enhancement." Her clinics often lack the oversight of traditional psychiatric practices, raising ethical questions about informed consent and risk management. Yet, her ability to normalize ketamine’s use—particularly among those who might otherwise dismiss it as "just another drug"—has made her a polarizing figure in the psychedelic space.

Historical Background and Evolution

Ketamine’s journey from a Cold War-era anesthetic to a psychedelic darling is a story of serendipity and exploitation. Synthesized in the 1960s, it was initially celebrated for its rapid onset and dissociative effects, which made it ideal for battlefield medicine. By the 1970s, however, its recreational use became apparent, particularly in the underground club scene, where it was prized for its ability to induce a "K-hole"—a state of profound dissociation. Sangha’s work builds on this dual legacy, but her innovation lies in repackaging ketamine as a therapeutic tool rather than a party drug.

The modern psychedelic revival, fueled by studies on psilocybin and MDMA, created an opening for ketamine to be rebranded as a legitimate mental health treatment. Sangha capitalized on this shift, but unlike academic researchers, she framed ketamine not just as a treatment for depression or PTSD, but as a gateway to "expanded consciousness." Her clinics often incorporate elements of sensory deprivation, music, and even guided imagery, creating an experience that blurs the line between medicine and mysticism. This approach has been both celebrated for its creativity and criticized for its lack of empirical rigor.

Core Mechanisms: How It Works

At its core, ketamine’s therapeutic potential stems from its interaction with the NMDA receptor, a glutamate pathway in the brain. Unlike traditional antidepressants, which take weeks to alter serotonin levels, ketamine produces rapid antidepressant effects by promoting synaptic plasticity—a process linked to neurogenesis and mood regulation. Sangha’s clinics leverage this mechanism, but her emphasis on the "dissociative experience" suggests a belief that the psychedelic effects themselves are curative, a claim not universally supported by research.

What sets Sangha’s approach apart is her focus on the subjective experience of ketamine. She often describes the drug’s effects as a "reset button" for the mind, allowing patients to confront traumatic memories or cognitive patterns in a dissociated state. However, this method lacks the structured therapeutic framework of ketamine-assisted psychotherapy (KAP), where patients work with therapists to process their experiences post-session. Critics argue that Sangha’s model prioritizes the "trip" over clinical outcomes, risking emotional destabilization without proper integration.

Key Benefits and Crucial Impact

The ketamine queen phenomenon has undeniably accelerated public awareness of ketamine’s therapeutic potential, but its impact is a double-edged sword. On one hand, Sangha’s clinics have provided relief for individuals who’ve exhausted conventional treatments, particularly those with treatment-resistant depression or chronic pain. Her unfiltered advocacy has also challenged the stigma around psychedelics, pushing them further into the mainstream. On the other hand, her methods have sparked debates about the commercialization of mental health and the ethical implications of unregulated psychedelic experiences.

Sangha’s influence extends beyond her clinics. She has become a thought leader in the "psychedelic wellness" industry, collaborating with wellness influencers, tech entrepreneurs, and even some traditional therapists. Her ability to articulate the intangible benefits of ketamine—such as "cognitive flexibility" and "emotional liberation"—has resonated with a generation disillusioned by pharmaceutical antidepressants. Yet, the lack of long-term data on her specific protocols raises questions about sustainability and safety.

"Ketamine isn’t just a drug; it’s a tool for rewriting the narrative of your mind. The question isn’t whether it works—it’s whether you’re brave enough to let it."

—Jasveen Sangha, 2023

Major Advantages

• Rapid Relief: Unlike SSRIs, which can take weeks to show effects, ketamine often provides antidepressant benefits within hours, making it a lifeline for suicidal ideation.
• Neuroplasticity Boost: Ketamine’s ability to enhance synaptic connections offers potential for treating conditions like PTSD and OCD by "resetting" maladaptive neural pathways.
• Dissociative Insight: Sangha’s emphasis on the dissociative experience allows patients to access subconscious material, which can be therapeutic when guided properly.
• Low Abuse Potential: Compared to opioids or benzodiazepines, ketamine has a lower risk of addiction, though recreational use can still lead to dependency.
• Cultural Shift: Sangha’s work has normalized discussions about psychedelics in mental health, paving the way for further research and destigmatization.

Comparative Analysis

Future Trends and Innovations

The ketamine queen phenomenon is unlikely to fade, but its evolution will depend on regulatory scrutiny and scientific validation. As ketamine’s therapeutic applications expand, we may see Sangha’s model either absorbed into mainstream psychiatry or pushed further into the fringe. The FDA’s approval of esketamine (Spravato) for depression in 2019 was a turning point, but it also highlighted the need for rigorous standards—a gap that Sangha’s clinics currently fill with creativity rather than compliance.

Looking ahead, innovations in ketamine delivery—such as intranasal sprays or transdermal patches—could democratize access, potentially reducing the need for clinic-based experiences like those offered by Sangha. However, her influence may persist in the "experiential" space, where the emphasis remains on the subjective rather than the clinical. The rise of "ketamine bars" and wellness retreats suggests that Sangha’s approach will continue to shape how psychedelics are consumed, even if her specific methods face greater scrutiny.

Conclusion

Jasveen Sangha’s legacy as the ketamine queen is a testament to the power of psychedelics to disrupt conventional medicine. Her work has forced a conversation about the boundaries of therapy, the ethics of self-experimentation, and the role of subjectivity in healing. While her methods may not align with traditional psychiatric practices, they reflect a broader cultural shift toward personal agency in mental health. The question now is whether her influence will lead to greater innovation—or whether the backlash will push psychedelics back into the shadows.

One thing is certain: Sangha’s impact on the psychedelic landscape is irreversible. Whether she is remembered as a pioneer or a cautionary tale, her story underscores the tension between science and spirituality—a tension that defines the future of psychedelic medicine.

Comprehensive FAQs

Q: Is Jasveen Sangha’s ketamine therapy clinically approved?

A: No. While ketamine is FDA-approved for depression (as esketamine) and anesthesia, Sangha’s clinics operate outside traditional medical frameworks. They are not licensed psychiatric facilities, which raises concerns about safety and regulation.

Q: How does Sangha’s approach differ from traditional ketamine therapy?

A: Traditional ketamine-assisted psychotherapy (KAP) involves structured sessions with therapists to process experiences. Sangha’s model prioritizes the dissociative experience itself, often in non-clinical settings, with less emphasis on integration.

Q: Are there risks associated with Sangha’s ketamine sessions?

A: Yes. Risks include dissociation-induced anxiety, increased heart rate, and potential for emotional flooding without proper therapeutic support. Her lack of medical oversight also raises concerns about adverse reactions.

Q: Can ketamine help with conditions other than depression?

A: Research suggests potential benefits for PTSD, chronic pain, and OCD, but most studies focus on depression. Sangha’s clinics market ketamine for "cognitive enhancement" and "spiritual exploration," which lack robust clinical backing.

Q: How has Sangha influenced the psychedelic movement?

A: She has normalized ketamine’s use beyond medical contexts, blending wellness culture with psychedelics. Her social media presence has also accelerated public interest, though her methods have sparked debates about commercialization and ethics.

Q: What is the future of ketamine therapy like Sangha’s?

A: If regulated properly, her model could evolve into a hybrid of experiential and clinical therapy. However, increased scrutiny may push her toward more evidence-based practices or force her to operate entirely outside mainstream medicine.

• Jasveen Sangha
• dissociative drugs
• ketamine queen
• ketamine therapy
• mental health innovation
• psychedelic advocacy
• psychedelic culture
• psychedelic research
• underground medicine